Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth factor insensitivity in renal failure.

R Rabkin1

  • 1Research Service Veterans Affairs Palo Alto Health Care System, California, USA. rabkin@leland.stanford.edu

Renal Failure
|August 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of depression in HIV+men: Literature review and report of an ongoing study of testosterone replacement therapy.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2013
Same author

Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C.

International journal of STD & AIDS·2011
Same author

A note on tick-bite fever.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2010
Same author

Increased workload fully activates the blunted IRS-1/PI3-kinase/Akt signaling pathway in atrophied uremic muscle.

Kidney international·2008
Same author

Growth hormone treatment prevents osteoporosis in uremic rats.

Histology and histopathology·2007
Same author

Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia.

Kidney international·2006
Same journal

Pentoxifylline and cardiorenal outcomes in advanced CKD with untreated dyslipidemia: a longitudinal cohort study.

Renal failure·2026
Same journal

Risk factors and temporal trends of early urological complications after kidney transplantation: a 15-year single-center cohort study.

Renal failure·2026
Same journal

SGLT2 inhibitors and chronic kidney disease: a narrative review of nephroprotective mechanisms from hemodynamics to metabolism.

Renal failure·2026
Same journal

Hypoxia-inducible factor-1α promotes epithelial-to-mesenchymal transition through upregulating cathepsin S expression in diabetic kidney disease.

Renal failure·2026
Same journal

Development and validation of a dual-channel deep learning for continuous acute kidney injury prediction in critically ill patients.

Renal failure·2026
Same journal

Relaxin inhibits renal interstitial fibrosis and promotes fatty acid metabolism after UUO <i>via</i> the AMPK/PGC1α signaling pathway.

Renal failure·2026
See all related articles

Patients with advanced chronic renal failure experience endocrine and metabolic issues, including growth retardation. Understanding growth factor resistance is key to improving treatment with recombinant hormones.

Area of Science:

  • Nephrology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Advanced chronic renal failure (CRF) causes significant endocrine and metabolic abnormalities.
  • These include growth retardation, bone disease, and disruptions in lipid, carbohydrate, and protein metabolism.
  • Hormone and growth factor dysregulation and altered target organ sensitivity are central to these complications.

Purpose of the Study:

  • To review the impact of advanced renal failure on tissue sensitivity to key hormones.
  • To explore the mechanisms underlying growth factor resistance in CRF.
  • To inform therapeutic strategies for improving hormone sensitivity in renal failure patients.

Main Methods:

  • Review of current knowledge on endocrine and metabolic changes in advanced CRF.

Related Experiment Videos

  • Analysis of the impact of renal failure on tissue sensitivity to insulin, growth hormone (GH), and insulin-like growth factor I (IGF-I).
  • Discussion of therapeutic implications of understanding growth factor resistance.

    • Main Results:

    • Advanced CRF leads to resistance in target organs to the actions of insulin, GH, and IGF-I.
    • This resistance necessitates higher doses of recombinant growth factors, increasing side effect risks.
    • A deeper understanding of resistance mechanisms is crucial for effective treatment.

    Conclusions:

    • Addressing end-organ resistance is a critical therapeutic target in advanced CRF.
    • Restoring sensitivity to endogenous or low-dose recombinant hormones could improve patient outcomes.
    • Further research into the mechanisms of growth factor resistance is warranted.